Story thread · 2 reports / 2 sources
Yarrow brings in more cash; AbbVie drug succeeds in menstrual migraine trial
endpts.com · 3d
Plus news about Sino Biopharm and AtomVie. Yarrow gets more money: New Haven-based Yarrow Bioscience priced a $150 million offering at $26 per share {$YARW}, about $2.50 below its Thursday closing ...
First report: Yarrow Bioscience prices $150M public offering of common stock at $26 per share — seekingalpha.com, 4d
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.